Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis
Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis
复制标题
DOI：
10.1016/j.ijrobp.2004.01.032
复制
发表时间：
2004-08-01
影响因子：
7
通讯作者：
Ohto, M
中科院分区：
文献类型：
--
作者：
Kato, H;Tsujii, H;Ohto, M
目的：在一期-二期试验中评价碳离子放射治疗肝癌的毒性和抗肿瘤效果。方法和材料：1995年6月至1997年2月，24例经组织病理学证实的肝细胞癌患者在5周内接受了15次碳离子放射治疗，剂量逐步递增。II期10例，IIIA期6例，IVA期8例。使用通用毒性标准、放射治疗肿瘤学小组/欧洲癌症研究和治疗组织标准和Child-Pugh评分来评估毒性。结果：中位随访71个月(63~83个月)，无严重不良反应发生，无治疗相关死亡。治疗开始后，Child-Pugh评分没有增加2分。在所有患者中，78%和75%的患者在早期和晚期分别没有增加>；1分。总的肿瘤有效率为71%。1、3、5年局部控制率和总生存率分别为92%和92%、81%和50%、81%和25%。结论：碳离子放射治疗肝癌安全有效。需要使用更大的受试者组进行额外的临床研究来确认治疗效果。(C)2004年爱思唯尔公司。
Purpose: To evaluate the toxicity and antitumor effect of carbon ion radiotherapy for hepatocellular carcinoma within a Phase I-II trial.Methods and Materials: Between June 1995 and February 1997, 24 patients with histopathologically proven hepatocellular carcinoma were treated to 15 fractions within 5 weeks in a step-wise dose-escalation study. The disease stage was Stage II in 10, IIIA in 6, and IVA in 8 patients. The Common Toxicity Criteria, Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer criteria, and Child-Pugh score were used to evaluate toxicity. The antitumor effect was evaluated by the tumor response, cumulative local control, and survival rates.Results: During a median follow-up of 71 months (range, 63-83 months), no severe adverse effects and no treatment-related deaths occurred. The Child-Pugh score did not increase by >2 points after the start of therapy. In 78% and 75% of all patients, the score did not increase by >1 point in the early and late phase, respectively. The overall tumor response rate was 71%. The local control and overall survival rate was 92% and 92%, 81% and 50%, and 81% and 25% at 1, 3, and 5 years, respectively.Conclusion: Carbon ion radiotherapy appears safe and effective for patients with hepatocellular carcinoma. Additional clinical studies using a larger subject group are required to confirm the therapeutic efficacy. (C) 2004 Elsevier Inc.